Recurrence of immune thrombocytopenia at the time of SARS-CoV-2 infection

Zulfiqar A-A, Lorenzo-Villalba N, Hassler P, Andrès E (2020) Immune thrombocytopenic purpura in a patient with Covid-19. N Engl J Med 382:e43

Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W et al (2020) Coagulopathy and antiphospholipid antibodies in patients with Covid-19. N Engl J Med 382:e38

Middeldorp S, Coppens M, van Haaps TF, Foppen M, Vlaar AP, Müller MCA et al (2020) Incidence of venous thromboembolism in hospitalized patients with COVID–19. J Thromb Haemost. https://doi.org/10.1111/jth.141888

Wong RSM, Saleh MN, Khelif A, Salama A, Portella MSO, Burgess P, Bussel JB (2017) Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study. Blood. 130(23):2527–2536

Pavord S, Thachil J, Hunt B, Murphy M, Lowe G, Laffan M et al (2020) Practical guidance for the management of adults with immune thrombocytopenia during the COVID-19 pandemic. Br J Haematol. https://doi.org/10.1111/bjh.16775

Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al (2020) Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. https://doi.org/10.1001/jamainternmed.2020.0994